Monday, October 19, 2009: 3:00 PM
Grand Ballroom, Salons 1 & 2 (Renaissance Hollywood Hotel)
* Candidate for the Lee B. Lusted Student Prize Competition
Click on the Individual Presentation Titles to view the abstract details.
Click here to view Poster Number Acronyms
* PATIENTS AND THE PUBLIC AGREE ON THE SEVERITY OF DEPRESSION, BUT PATIENTS WILL PAY MORE FOR TREATMENT
Yvette Peeters, MA, Leiden University Medical Center, Leiden, Netherlands, Peter A. Ubel, MD, VA Ann Arbor Healthcare System & University of Michigan, Ann Arbor, MI, Laura J. Damschroder, MS, MPH, VA Ann Arbor Healthcare System, Ann Arbor, MI and Dylan Smith, PhD, Stony Brook University, Stony Brook, NY
* THE COST-EFFECTIVENESS OF GROUP COGNITIVE BEHAVIOURAL THERAPY FOR POST NATAL DEPRESSION
Matt Stevenson, PhD1, Alison Scope, PhD1 and Paul A. Sutcliffe, PhD2, (1)The School of Health and Related Research, University of Sheffield., Sheffield, England, (2)University of Warwick, Coventry, United Kingdom
* A MODELED ECONOMIC EVALUATION OF ALTERNATIVE STRATEGIES TO REDUCE SUDDEN CARDIAC DEATH AMONG CHILDREN TREATED FOR ATTENTION DEFICIT AND HYPERACTIVITY DISORDER
Peter Denchev, PhD1, Jonathan Kaltman, MD2, Michael Schoenbaum1 and Benedetto Vitiello1, (1)NIMH/NIH, Rockville, MD, (2)Nhlbi/NIH, Bethesda, MD
* SAFETY AND EFFICACY OF EXTENDED-DURATION ANTIVIRAL CHEMOPROPHYLAXIS FOR PANDEMIC AND SEASONAL INFLUENZA
Nayer Khazeni, MD, MS1, Dena M. Bravata, MD, MS1, Jon-Erik C. Holty, MD, MS1, Timothy M. Uyeki, MD, MPH, MPP2 and Michael K. Gould, MD, MS3, (1)Stanford University, Stanford, CA, (2)Centers for Disease Control and Prevention, Atlanta, GA, (3)Veterans Affairs Palo Alto Health Care System and Stanford University, Palo Alto, CA
* ANTI-TNF-ALPHA DRUGS FOR TREATMENT OF CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Nazila Assasi, MD, PhD1, Gordon Blackhouse, MSc.2, Feng Xie3, Kathryn Gaebel, MSc4, John K. Marshall, MD2, E. Jan Irvine, MD, FRCP, (C), MSc5, Diana Robertson2, Kaitryn Campbell, BSc.6, Robert Hopkins, MA2 and Ron Goeree, MA2, (1)St. Joseph's Healthcare/McMaster University, Hamilton, ON, Canada, (2)McMaster University, Hamilton, ON, Canada, (3)St Josephs Healthcare/McMaster University, Hamilton, ON, Canada, (4)St Josephs Healthcare, Hamilton, ON, Canada, (5)University of Toronto, Toronto, ON, Canada, (6)PATH Research Institute, Hamilton, ON, Canada
* HEALTH CONDITION IMPACTS AS MEASURED BY COMMON HEALTH UTILITY INDEXES IN A CROSS-SECTIONAL SURVEY: DISAPPOINTING NEWS FOR COST-EFFECTIVENESS ANALYSES
Janel Hanmer, PhD1, Adam Paulsen1, Dasha Cherepanov, PhD1, Mari Palta, PhD1, Robert M. Kaplan, PhD2, David Feeny, PhD3 and Dennis G. Fryback, PhD4, (1)University of Wisconsin, Madison, WI, (2)University of California Los Angeles, Los Angeles, CA, (3)Health Utilities, Inc., and Kaiser Permanente Northwest Center for Health Research, Portland, OR, (4)University of Wisconsin - Madison, Madison, WI
* VALUE OF INFORMATION MODEL TO ASSESS THE POTENTIAL PUBLIC HEALTH IMPACT OF CLINICAL TRIALS IN NEUROLOGY
Ravi Dhurjati, PhD1, Gregory P. Samsa, PhD1 and David B. Matchar, MD2, (1)Duke University Medical Center, Durham, NC, (2)Duke-NUS Graduate Medical School, Singapore, Singapore
* THE COST-EFFECTIVENESS OF BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUGS (DMARDS) COMPARED TO CONVENTIONAL DMARDS: A SYSTEMATIC REVIEW OF ECONOMIC EVALUATIONS
Gabrielle van der Velde, DC, PhD1, Márcio Machado, PhD1, Ba' Pham, MSc, PhD, (c)2, Luciano Ieraci, MSc1, William Witteman, MISt1 and Murray D. Krahn, MD, MSc1, (1)University of Toronto, Toronto, ON, Canada, (2)Toronto Health Economics and Technology Assessment Collaborative, Toronto, ON, Canada
* HIP AND KNEE OSTEOARTHRITIS: CAN DECISION AIDS HELP PATIENTS MAKE A QUALITY TREATMENT CHOICE?
Catharine F. Clay, MA, BSN1, Ivan Tomek, MD1, Stephen Kantor, MD1 and Stephen Kearing, MS2, (1)Dartmouth Hitchcock Medical Center, Lebanon, NH, (2)Dartmouth Medical School, Lebanon, NH
* COST-EFFECTIVENESS OF FIRST-LINE TREATMENT FOR OSTEOPOROSIS WHEN THE DRUG GOES GENERIC
Gunhild Hagen, MPhil1, Torbjørn Wisløff, M.Sc.1, Ivar Sønbø Kristiansen, MD, PhD, MPH2 and Marianne Klemp Gjertsen, MD, PhD3, (1)Norwegian Knowledge Centre for the Health Services, Oslo, Norway, (2)Institute of Health Economics, N-0317 Oslo, Denmark Norway, (3)University of Oslo, Oslo, Norway
* COST-EFFECTIVENESS ANALYSIS OF ANTI-OBESITY TREATMENTS: ORLISTAT, SIBUTRMAINE AND BEHAVIORAL THERAPY
Hemalkumar B. Mehta, BS1, Rohan C. Parikh, BS1 and Sujit S. Sansgiry, PhD2, (1)University of Houston, Houston, TX, (2)College of Pharmacy, University of Houston, Houston, TX
* REDUCING DISPARITIES IN DECISION MAKING THROUGH INTERPRETERS FOR LIMITED ENGLISH PROCIENT PATIENTS
Stergios Roussos, PhD, MPH1, Mary-Rose Mueller, PhD, RN2, Linda Hill, MD, MPH3, Nadia Salas, MPH4 and Mel Hovell, PhD, MPH4, (1)San Diego State University, Merced, CA, (2)University of San Diego, San Diego, CA, (3)Ucsd, San Diego, CA, (4)San Diego State University, San Diego, CA
* THE SAFETY AND EFFICACY OF RECOMBINANT ACTIVATED FACTOR VIIA FOR CARDIAC SURGERY: PATTERNS OF USE AND COMPARATIVE EFFECTIVENESS REVIEW
Veronica Yank, MD1, Craig V. Tuohy, BS1, Aaron Logan, MD, PhD2, Dena M. Bravata, MD, MS1, Kristan Staudenmayer, MD1, Robin Eisenhut, BA1, Vandana Sundaram, MPH3, Donal McMahon, MS, MSc1, Ingram Olkin, PhD4, Kathryn M. McDonald, MM1, Douglas K. Owens, MD, MS5 and Randall S. Stafford, MD, PhD2, (1)Stanford University, Stanford, CA, (2)Stanford University School of Medicine, Stanford, CA, (3)VA Palo Alto Health Care System, Palo Alto, CA, (4)Stanford University, Palo Alto, CA, (5)Veterans Affairs Palo Alto Health Care System and Stanford University, Stanford, CA
* INCREMENTAL COST-EFFECTIVENESS OF MORE MONTHLY DOSES OF VARDENAFIL
Sherrie L. Aspinall, PharmD, MSc1, Kenneth J. Smith, MD, MS2, Francesca E. Cunningham, PharmD1 and Chester B. Good, MD, MPH1, (1)VA Pharmacy Benefits Management Services, Hines, IL, (2)University of Pittsburgh School of Medicine, Pittsburgh, PA
* ECONOMIC CONSEQUENCES OF EARLY VERSUS LATE TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) IN THE US
Yanni F. Yu, MA, MS, Bristol-Myers Squibb, Wallingford, CT, Yong Yuan, PhD, Bristol-Myers Squibb, Plainsboro, NJ and Jeffrey S. McCombs, PhD, University of Southern California, Los Angeles, CA
* THE ECONOMIC VALUE OF A POTENTIAL BIOMARKER FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Mehdi Najafzadeh, MSc, MA, Carlo A. Marra, PharmD, PhD, Larry D. Lynd, PhD, Mohsen Sadatsafavi, MD, MHSc and Don D. Sin, MD, University of British Columbia, Vancouver, BC, Canada
* POPULATION-BASED LONG-TERM HEALTH CARE COSTS ATTRIBUTABLE TO HEPATITIS C
Hla-Hla Thein, MD, MPH, PhD, University of New South Wales and University of Toronto, Sydney, Australia, Brandon Zagorski, MSc, BMZ Analytics, Toronto, ON, Canada, Mel Krajden, MD, University of British Columbia, Vancouver, BC, Canada and Murray D. Krahn, MD, MSc, University of Toronto, Toronto, ON, Canada
* COMPARISON OF PEDIATRIC HIV COSTS IN MONO THERAPY, COMBINATION THERAPY AND HAART ERAS
Leslie S. Wilson, PhD, Maria Christenson, PharmD, Rituparna Basu, Ph.D., Lori Hensic, Pharm.D., Carly J. Paoli, Pharm.D., Diane Wara, M.D. and Judith Moskowitz, Ph.D., University of California San Francisco, San Francisco, CA
* TEACHING DECISION ANALYSIS TO PRE-CLINICAL MEDICAL STUDENTS
Douglas B. Fridsma, MD, PhD, Arizona State University, Phoenix, AZ and Howard Silverman, MD, MS, University of Arizona College of Medicine-Phoenix in partnership with Arizona State University, Phoenix, AZ
* PARTICIPATION IN CANCER CLINICAL TRIALS
Margaret M. Byrne, PhD, Julie Kornfeld, MPH, Stefan Gluck, MD, PhD, Judith Hurley, MD and Michael Antoni, PhD, University of Miami, Miami, FL
* VALUES-BASED DECISION MAKING:THE APPLICATION OF A MULTI CRITERIA DECISION ANALYTIC TOOL TO PROSTATE CANCER SCREENING
Glenn P. Salkeld, PhD1, Michelle Cunich, PhD1, Jack Dowie, PhD2, Helena Britt, PhD1, Joan Henderson, PhD1 and Kirsten Howard, PhD1, (1)The University of Sydney, Sydney, Australia, (2)London School of Hygiene and Tropical Medicine, London, United Kingdom
* PATIENTS' PERSPECTIVES ON DECISION MAKING SURROUNDING IMPLANTABLE CARDIOVERTER DEFIBRILLATORS: A QUALITATIVE STUDY
Dan D. Matlock, MD1, Carolyn Nowels, MSPH1, Debbi Main, PhD2, Pamela Peterson, MD, MSPH3, Fred Masoudi, MD, MSPH3 and Jean S. Kutner, MD, MSPH1, (1)The University of Colorado Denver, Aurora, CO, (2)University of Colorado Denver, Denver, CO, (3)Denver Health Medical Center, Division of Cardiology, Denver, CO
* OPEN-ENDED VS. CLOSED-ENDED QUESTIONS TO MEASURE KKNOWLEDGE OF LIKELIHOOD OF BENEFITS AND HARMS
Carol Cosenza, MSW1, Karen R. Sepucha, PhD2, Carrie A. Levin, PhD3 and Svea Stromme1, (1)University of Massachusetts Boston, Boston, MA, (2)Massachusetts General Hospital, Boston, MA, (3)Foundation for Informed Medical Decision Making, Boston, MA
* INTEGRATING DECISION SUPPORT INTO CLINICAL CARE FOR PATIENTS CONSIDERING ADJUVANT THERAPY FOR BREAST CANCER
Stephen Kearing, MS1, E. Dale Collins, MD2, Allison J. Hawke1, Gary N. Schwartz, MD2, Peter Kaufman, MD2, Bradley A. Arrick, MD, PhD2, Catharine F. Clay, MA, BSN2, Alyssa S. Stevens, BS2, Susan Berg, MS, CGC2 and Hilary A. Llewellyn-Thomas, PhD1, (1)Dartmouth Medical School, Lebanon, NH, (2)Dartmouth Hitchcock Medical Center, Lebanon, NH
* PATIENT AND PHYSICIAN PRIORITIZATION OF PREVENTIVE SERVICES DURING ANNUAL CHECK UPS
Deirdre A. Shires, MPH, MSW1, Ronak Vashi1, Kurt Stange, MD2, George Divine, PhD1, Greg Cooper, MD2, Susan A. Flocke, PhD2 and Jennifer Elston Lafata, PhD1, (1)Henry Ford Health System, Detroit, MI, (2)Case Western Reserve University, Cleveland, OH
* USING A DISCRETE CHOICE EXPERIMENT TO UNDERSTAND PRIORITY SETTING DECISIONS ABOUT PERSONAL SUPPORT AND HOMEMAKING SERVICES IN CANADA
Michele A. Kohli, PhD1, Deborah Marshall, PhD2, Jan Barnsley, PhD3 and Peter C. Coyte, PhD3, (1)i3 Innovus, Burlington, ON, Canada, (2)University of Calgary, Calgary, AB, Canada, (3)University of Toronto, Toronto, ON, Canada
* IDEAL AFFECT MEDIATES AGE-RELATED CULTURAL DIFFERENCES IN PHYSICIAN PREFERENCE
Tamara L. Sims, MA1, Jeanne L. Tsai, PhD1 and Mary K. Goldstein, MD, MS2, (1)Stanford University, Stanford, CA, (2)Stanford University, VA Palo Alto Health Care System, Stanford, CA
* EUROQOL (EQ-5D) HEALTH UTILITY SCORES FOR PATIENTS WITH MIGRAINE
Ruifeng Xu, PhD1, Ralph P. Insinga, PhD1, Henry Hu2, Wendy Golden3 and Min Huang, PHD4, (1)Merck Research Laboratories, North Wales, PA, (2)Merck Research Laboratories, West Point, PA, (3)Merck Research Laboratories, Whitehouse Station, NJ, (4)Merck & Co. Inc., North Wales, PA
* IMPACT OF TREATMENT INTERRUPTIONS AND MEGA-ART ON HEALTH-RELATED QUALITY OF LIFE IN THE OPTIMA TRIAL
Vilija R. Joyce, MS1, Paul G. Barnett, PhD1, Ahmed M. Bayoumi, MD, MSc2, Susan C. Griffin, MSc, BSc3, Gillian D. Sanders, PhD4, Huiying Sun, PhD5, Mark Holodniy, MD6, Sheldon T. Brown, MD7, D. William Cameron, MD8, Mark Sculpher, PhD3, Mike Youle, MB, ChB9, Aslam H. Anis, PhD10 and Douglas K. Owens, MD, MS11, (1)VA Palo Alto Health Care System, Menlo Park, CA, (2)Centre for Research on Inner City Health, the Keenan Research Centre in the Li Ka Shing Knowledge Institute, Toronto, ON ON ON, Canada Canada Canada, (3)University of York, York, United Kingdom, (4)Duke, Durham, NC, (5)St. Paul's Hospital, Vancouver, BC, Canada, (6)VA Palo Alto Health Care System, Palo Alto, CA, (7)Bronx VA Medical Center, Bronx, NY, (8)Ottawa Hospital, Ottawa, ON, Canada, (9)Royal Free Hospital, London, United Kingdom, (10)University of British Columbia, Vancouver, BC, Canada, (11)Veterans Affairs Palo Alto Health Care System and Stanford University, Stanford, CA
* SOME RESULTS ARE MORE EQUAL THAN OTHERS: COMPARISON OF ICER ESTIMATES AND CEACS OBTAINED FROM A MODEL IMPLEMENTED IN MICROSOFT EXCEL AND TREEAGE
Matthias Bischof, MPharm, MSc, PhD1, Morgan Lim, MA1, Ilia Ferrusi, BSc2, Natasha Burke1, G. Blackhouse1, Ron Goeree, MA1 and J Tarride1, (1)McMaster University, Hamilton, ON, Canada, (2)Centre for Evaluation of Medicines, Hamilton, ON, Canada
